AnalystBook Research · Company Intelligence

Citius Pharmaceuticals, Inc.

CTXRNasdaq

Built from Citius Pharmaceuticals, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Net income decreased 0.8% to ($39.7M), while Operating cash flow increased 5.8% to ($26.6M).

The read at a glance✓ Audited against SEC data
  • Scale — FY2025 revenue N/AWatch
  • Profitability — Net income ($39.7M)Watch
  • Cash generation — Free cash flow ($26.6M)Note
  • Accounting — No applicable forensic screenNote
  • Insiders — 0 buys; 0 sells in 365 daysNote
  • Capital — Comparable payout data unavailableNote

Business

Citius Pharmaceuticals, Inc.: We, through Citius Oncology, have one approved product, LYMPHIR, that we launched in December 2025, and have an unproven business strategy, and a limited operating history upon which to evaluate it, and may never achieve successful commercialization of LYMPHIR or any future product candidates or achieve or maintain profitability.

Latest filings

  • 8-K · Company announcement2026-08-21
  • 8-K · Company announcement2026-08-14
  • 10-Q · Quarterly report2026-08-14
  • 8-K · Company announcement2026-08-05
  • 8-K · Company announcement2026-06-01
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Citius Pharmaceuticals, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full CTXR record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.